Veru Inc. (VERU) Insider Trading Activity

NASDAQ$2.16
Market Cap
$36.83M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
370 of 849
Rank in Industry
216 of 491

VERU Insider Trading Activity

VERU Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$4,842
1
100
Sells
$0
0
0

Related Transactions

BARNETTE K GARYChief Scientific Officer
1
$4,842
0
$0
$4,842

About Veru Inc.

Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of …

Insider Activity of Veru Inc.

Over the last 12 months, insiders at Veru Inc. have bought $4,842 and sold $0 worth of Veru Inc. stock.

On average, over the past 5 years, insiders at Veru Inc. have bought $36,963 and sold $1.17M worth of stock each year.

Highest buying activity among insiders over the last 12 months: BARNETTE K GARY (Chief Scientific Officer) — $4,842.

The last purchase of 1,800 shares for transaction amount of $4,842 was made by BARNETTE K GARY (Chief Scientific Officer) on 2026‑08‑13.

List of Insider Buy and Sell Transactions, Veru Inc.

2026-08-13PurchaseBARNETTE K GARYChief Scientific Officer
1,800
0.0078%
$2.69
$4,842
-8.52%
2025-02-19PurchaseRankowitz Michael Ldirector
54,721
0.0396%
$0.58
$31,919
-31.50%
2025-02-18PurchaseRankowitz Michael Ldirector
95,279
0.0662%
$0.55
$52,432
-25.23%
2024-05-24SaleSTEINER MITCHELL SHUSTERPresident and CEO
63,379
0.042%
$1.23
$78,102
-39.59%
2024-05-24PurchaseFISCH HARRYChief Corporate Officer
4,000
0.0027%
$1.25
$5,000
-39.59%
2024-05-24PurchaseBARNETTE K GARYChief Scientific Officer
5,000
0.0036%
$1.34
$6,697
-39.59%
2024-05-23SaleSTEINER MITCHELL SHUSTERPresident and CEO
300
0.0002%
$1.35
$405
-41.46%
2024-05-22SaleSTEINER MITCHELL SHUSTERPresident and CEO
6,504
0.0045%
$1.39
$9,018
-45.69%
2024-05-17SaleSTEINER MITCHELL SHUSTERPresident and CEO
28,066
0.0177%
$1.32
$36,988
-42.88%
2024-05-16SaleSTEINER MITCHELL SHUSTERPresident and CEO
59,788
0.0403%
$1.41
$84,128
-44.96%
2024-05-15SaleSTEINER MITCHELL SHUSTERPresident and CEO
84,021
0.0585%
$1.50
$125,813
-48.67%
2024-05-15PurchaseFISCH HARRYChief Corporate Officer
6,711
0.0046%
$1.49
$9,999
-48.67%
2022-08-15SaleEisenberger Mario
100,000
0.1275%
$20.04
$2M
-77.36%
2021-08-17PurchaseLu Lucydirector
4,800
0.006%
$6.78
$32,542
+23.97%
2021-06-16SaleFISCH HARRY
100,000
0.1237%
$8.35
$835,300
-8.26%
2021-03-10PurchaseHyun Gracedirector
3,500
0.0048%
$14.09
$49,315
-40.69%
2021-02-12SaleSTEINER MITCHELL SHUSTERPresident and CEO
20,000
0.0267%
$20.88
$417,688
-59.84%
2020-12-16SaleSTEINER MITCHELL SHUSTERPresident and CEO
250,000
0.3447%
$9.69
$2.42M
-12.86%
2020-12-16SaleBARNETTE K GARYChief Scientific Officer
100,000
0.1515%
$10.65
$1.06M
-12.86%
2020-08-26PurchaseFISCH HARRY
5,000
0.0075%
$2.76
$13,800
+195.80%
Total: 333
*Gray background shows transactions not older than one year

Insider Historical Profitability

11.81%
BARNETTE K GARYChief Scientific Officer
2300
0.0135%
$4,968.0041
+9.69%
STEINER MITCHELL SHUSTERPresident and CEO
6942709
40.719%
$15M1239
+4.18%
DEARHOLT STEPHEN Mdirector
1978899
11.6062%
$4.27M622
<0.0001%
PARRISH O Bdirector
844849
4.955%
$1.82M95
+7.64%
FISCH HARRYChief Corporate Officer
774736
4.5438%
$1.67M341
+24.87%
BETHUNE DAVID Rdirector
435982
2.557%
$941,721.1290
+6.14%
KERBER JAMES Rdirector
421766
2.4737%
$911,014.5617
WALTON MICHAEL Rdirector
395056
2.317%
$853,320.9636
+9.73%
Rankowitz Michael Ldirector
250000
1.4662%
$540,000.0020
<0.0001%
PEERSCHKE ELGARdirector
145520
0.8535%
$314,323.2040
+18.42%
LOVE ANDREW S JRdirector
114926
0.674%
$248,240.16100
<0.0001%
GARGIULO WILLIAM R JRdirector
102500
0.6012%
$221,400.0042
<0.0001%
Greco MicheleCAO and CFO
96178
0.5641%
$207,744.4830
+101.86%
HAINES DANIELChief Financial Officer
83931
0.4923%
$181,290.9660
+24.55%
King Karen LouisePresident and CEO
69500
0.4076%
$150,120.0020
<0.0001%
Felch Donnadirector
64382
0.3776%
$139,065.1227
+6.27%
LEEPER MARY ANNdirector
48000
0.2815%
$103,680.00117
Socorro Jesusdirector
32500
0.1906%
$70,200.0050
+9.61%
Hyun Gracedirector
14790
0.0867%
$31,946.4010
<0.0001%
Lu Lucydirector
9800
0.0575%
$21,168.0020
+27.52%
POPE MICHAELVP and General Manager
250
0.0015%
$540.00225
+32%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

Veru Inc.
(VERU)
$2,542,362
111
11.81%
$36.83M
$156,891,025
80
-24.91%
$36.3M
$84,911,583
59
17.82%
$37.44M
$693,326
47
-16.24%
$40.24M
$6,204,522
45
1.91%
$36.5M

VERU Institutional Investors: Active Positions

Increased Positions21+21%2M+50.42%
Decreased Positions42-42%1M-33.27%
New Positions7New1MNew
Sold Out Positions24Sold Out471,548Sold Out
Total Postitions79-21%4M+17.15%

VERU Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$1,454.004%640,687-30%2025-09-30
Sheets Smith Investment Management$731.002.01%322,084+319,850+14,317.37%2025-09-30
Osaic Holdings, Inc.$591.001.63%260,319+234,037+890.48%2025-09-30
Millennium Management Llc$526.001.45%231,602-30,547-11.65%2025-09-30
Oppenheimer & Co Inc$436.001.2%192,168+60,866+46.36%2025-09-30
Summit Financial, Llc$372.001.02%163,852+163,852New2025-09-30
Gsa Capital Partners Llp$368.001.01%162,226+162,226New2025-09-30
Geode Capital Management, Llc$362.001%159,353-1,281-0.8%2025-09-30
Pvg Asset Management Corp$360.000.99%158,810-5,927-3.6%2025-09-30
Ikarian Capital, Llc$324.000.89%142,523<1<0.01%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

No data is available at this moment.

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.